Literature DB >> 19589269

Advanced glycation end-products enhance calcification in vascular smooth muscle cells.

X Ren1, H Shao, Q Wei, Z Sun, N Liu.   

Abstract

Advanced glycation end-products (AGEs), senescent macroprotein derivatives formed at an accelerated rate in diabetes, are closely associated with vascular calcification in humans. In this study, the hypothesis that AGEs enhance calcification in cultured vascular smooth muscle cells (VSMCs) was tested. Using real-time polymerase chain reaction (PCR) and specific protein assays, it was demonstrated that rat aortic VSMCs incubated with AGEs exhibited an increased expression of the AGE receptor (RAGE) and typical bone proteins, such as osteopontin and alkaline phosphatase. Incubation with AGEs also enhanced calcium accumulation in VSMCs in time- and dose-dependent manners. These AGEs-mediated changes in VSMCs were partially attenuated by a neutralizing antibody to RAGE. The results suggest that AGEs that accumulate in diabetes could elicit the osteoblastic differentiation of VSMCs, thereby contributing to vascular calcification via the RAGE pathway. Interruption of the AGE-RAGE interaction might be a promising target for therapeutic intervention to prevent diabetic vascular calcification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589269     DOI: 10.1177/147323000903700329

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  27 in total

1.  Arterial calcification is driven by RAGE in Enpp1-/- mice.

Authors:  Denise L Cecil; Robert A Terkeltaub
Journal:  J Vasc Res       Date:  2010-11-23       Impact factor: 1.934

Review 2.  Vascular calcification: pathophysiology and risk factors.

Authors:  Neal X Chen; Sharon M Moe
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 3.  Calcific aortic valve stenosis: methods, models, and mechanisms.

Authors:  Jordan D Miller; Robert M Weiss; Donald D Heistad
Journal:  Circ Res       Date:  2011-05-27       Impact factor: 17.367

4.  Vascular scaffolds with enhanced antioxidant activity inhibit graft calcification.

Authors:  Bin Jiang; Rachel Suen; Jiao-Jing Wang; Zheng J Zhang; Jason A Wertheim; Guillermo A Ameer
Journal:  Biomaterials       Date:  2017-08-14       Impact factor: 12.479

5.  Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients.

Authors:  Mohamed M Nasrallah; Amal R El-Shehaby; Noha A Osman; Mona M Salem; Amr Nassef; Usama A A Sharaf El Din
Journal:  Int Urol Nephrol       Date:  2011-06-04       Impact factor: 2.370

Review 6.  RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy.

Authors:  Agbor Ndip; Fiona L Wilkinson; Edward B Jude; Andrew J M Boulton; M Yvonne Alexander
Journal:  Diabetologia       Date:  2014-08-12       Impact factor: 10.122

7.  Advanced glycation end products promote human aortic smooth muscle cell calcification in vitro via activating NF-κB and down-regulating IGF1R expression.

Authors:  Yi Wang; Zhen-yu Zhang; Xiao-qing Chen; Xiang Wang; Heng Cao; Shao-wen Liu
Journal:  Acta Pharmacol Sin       Date:  2013-02-18       Impact factor: 6.150

Review 8.  RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.

Authors:  Gowri Palanissami; Solomon F D Paul
Journal:  Horm Cancer       Date:  2018-07-09       Impact factor: 3.869

Review 9.  Role of AGEs in the progression and regression of atherosclerotic plaques.

Authors:  Zhong-Qun Wang; Le-le Jing; Jin-Chuan Yan; Zhen Sun; Zheng-Yang Bao; Chen Shao; Qi-Wen Pang; Yue Geng; Li-Li Zhang; Li-Hua Li
Journal:  Glycoconj J       Date:  2018-07-10       Impact factor: 2.916

10.  Tuning three-dimensional collagen matrix stiffness independently of collagen concentration modulates endothelial cell behavior.

Authors:  Brooke N Mason; Alina Starchenko; Rebecca M Williams; Lawrence J Bonassar; Cynthia A Reinhart-King
Journal:  Acta Biomater       Date:  2012-08-16       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.